Cardiomyopathy accounts for a high proportion of patients diagnosed and treated in cardiology department, but compared with hypertension and coronary heart disease, the understanding of cardiomyopathy is far from enough. Recently, the project of improving the standard of diagnosis and treatment of cardiomyopathy in Zhongshan Hospital affiliated to Fudan University was officially launched, aiming to focus on the diagnosis and treatment process, diagnosis ability, accurate identification and improvement of cognition, and comprehensively promote the standard diagnosis and treatment of cardiomyopathy in China. The data shows that the prevalence rate of hypertrophic cardiomyopathy in China is 0.16%, and the prevalence rate adjusted by age and sex is 80/100000. It is estimated that there are more than 1 million adult hypertrophic cardiomyopathy patients in China. The prevalence of dilated cardiomyopathy is estimated to be 1.2 per 10000 people. In order to standardize the clinical diagnosis and treatment of cardiomyopathy and improve the clinicians' grasp of diagnosis and treatment technology, the Cardiovascular Health Alliance and the Cardiovascular Health Research Institute of Suzhou Industrial Park jointly launched the "Cardiomyopathy Diagnosis and Treatment Standards Improvement Project", which will be launched in hospitals nationwide. Academician Ge Junbo of Sun Yat-sen Hospital affiliated to Fudan University stressed that he hoped that the improvement project of cardiomyopathy norms could reach consensus in the industry, have a clear understanding of the diagnosis, treatment and prognosis of cardiomyopathy, and provide guidance for the industry. Hypertrophic cardiomyopathy is caused by changes in the molecular level of sarcomere, including changes in the ratio of myosin SRX/DRX status, excessive formation of myosin - actin transverse bridge, increased Ca2+ion sensitivity, and increased ATPase activity, which jointly promote hypercontractility of cardiac muscle cells, resulting in cardiac hypertrophy, and changes in clinical morphology and function. According to the changes of sarcomere, cardiac myosin inhibitor can reduce myocardial hypersystole, improve myocardial diastolic function and energy metabolism. Echocardiography plays an indispensable role in the diagnosis and differential diagnosis of hypertrophic cardiomyopathy, hemodynamic classification, systolic function evaluation, myocardial microcirculation evaluation and guiding surgical treatment. The standard cardiac ultrasound report can provide comprehensive support for the optimization of the diagnosis and treatment process of hypertrophic cardiomyopathy. At present, the symptoms of hypertrophic cardiomyopathy are not rare in China. However, doctors in primary hospitals have a low awareness of the disease, the prevalence of cardiac ultrasound is low, it is very easy to misdiagnose, and there is no management standard. Professor Huo Yong of the First Hospital of Peking University said that the "Cardiomyopathy diagnosis and treatment specification improvement project" will focus on standardizing the diagnosis and treatment process of cardiomyopathy, strengthen training to improve diagnosis and treatment ability, accurately identify and assist classification diagnosis and treatment, improve cognition and optimize long-term management, and will comprehensively improve the diagnosis and treatment standard of cardiomyopathy in China. At the same time, Professor Yang Jiefu of Beijing Hospital said that the project plans to promote standardized cardiomyopathy diagnosis and treatment process, write relevant expert consensus, carry out a series of activities such as cardiomyopathy diagnosis and screening, exchange training, etc., comprehensively assist clinicians in multi-disciplinary and multi-level interaction and communication, improve clinicians' diagnosis and treatment ability, enhance the high attention and attention of both doctors and patients to cardiomyopathy, and promote the early detection of patients with cardiomyopathy in China. Cardiomyopathy is a large category of diseases, which need to be accurately subdivided clinically. Multi-disciplinary joint writing of the diagnosis and treatment path and consensus of hypertrophic cardiomyopathy experts is the most important work content in the next step of the cardiomyopathy standard improvement project. In the future, the "Cardiomyopathy diagnosis and treatment standard improvement project" will also be launched in a batch of hospitals selected nationwide, striving to make contributions to the improvement of the diagnosis and treatment level of cardiomyopathy in China